The combination of such an algorithm with systematic and mpMRI-targeted biopsy procedures (STHLM3-MRI) resulted in reduced prostate cancer mortality and a contemporary decrease in overdiagnosis (by 69%), biopsy rates (by 8%), and the number of MRI procedures itself (by 36%), compared to a traditional screening strategy (PSA plus prostate mapping biopsy). This evidence concerns the gene KLK3 and Familial prostate cancer.